GOD-Perid method (Boehringer Mannheim) that is routinely used in our laboratory. All determinations were performed in duplicate with 10 L of CSF on the DT60 II and 100 L for the GOD-Perid method.
For this study 185 unselected, consecutive samples were analyzed. The mean difference for these two methods (Vitros DT60 II Ϫ GOD Perid) lies at Ϫ0.1 mmol/L (Ϫ1.8 mg/dL), with an SD of 0.39 mmol/L (7.0 mg/ dL) ( Fig. 1) . Linear regression statistics are as follows: (numbers in parentheses are for conventional units) slope, 1.076; intercept, Ϫ0.120 (Ϫ2.16); S y͉x , 0.361 (6.58); correlation coefficient, 0.935. Ten of the samples gave no value on the DT60 II [below the detection limit; Ͻ1.0 mmol/L (18 mg/dL)] and had to be excluded from the calculation.
The DT60 II seems to give somewhat higher values in the low range [Ͻ2 mmol/L (36 mg/dL)]; however, no trend can be seen on the whole. The picture in the low range might also be distorted because the two methods do not have the same detection limit. Therefore, samples in the low range where the difference would be negative cannot be calculated because they cannot be measured with the DT60 II. The DT60 II system appears to provide a reliable, accurate, and rapid method for determination of CSF glucose. 
Ralph Fingerhut

Comment on the Nature and Specificity of Bayer Corporation and Chiron Diagnostics hCG Immunoassays
To the Editor:
We wish to update information in the recent hCG review article (1), regarding the specificities and antibody configurations used in the Chiron Diagnostics and Bayer Corporation hCG immunoassays.
The review article depicted the diverse nature of the human chorionic gonadotropin (hCG) molecule. As described, a non-nicked hCG (the hormone), a nicked hCG, a free ␣-subunit, and a free ␤-subunit are present in blood samples, and the same molecules plus a ␤-core fragment occur in urine samples.
As described in the review article (1), commercial hCG assays sold in the United States use a variety of antibodies directed to different sites on hCG and related molecules. Some assays use antibodies to non-nicked hCG ("anti-hCG dimer"), others use antibodies to sites on hCG ␤-subunit common to hCG and its free ␤-subunit ("anti-common ␤1" and "anticommon ␤2"). Still other assays use antibodies to diverse epitopes on hCG subunits and fragments ("anticommon ␣", "anti ␤ C-terminal", "anti-free ␤", and "anti ␤-core fragment"). The combination of antibodies used by an hCG assay dictate the specificity of the assay and whether it detects non-nicked hCG only, nonnicked hCG and free ␤-subunit, nicked and non-nicked hCG only, or nicked and non-nicked hCG with free ␤-subunit and possibly ␤-core fragment.
In Table 2 of the review article, examples were given of antibody configurations and of the likely specificities of 54 commercial hCG-related immunoassays sold in the United States (1). The table was based totally on information in assay instruction booklets, on details from telephone technical support services, and on information published in reports. Here we make corrections to that table.
The Chiron Diagnostics Magic Lite TM total hCG assay uses a combination of anti-common ␤2 and anti-hCG dimer antibodies to capture antigens and an anti-common ␤1 antibody to label the captured molecules. This combination of antibodies detects nicked and non-nicked hCG, free ␤-subunit and urine ␤-core fragment, or all hCG␤-related molecules. The Chiron Diagnostics ACS:180 TM assay uses the same types of antibody, but with the capture and tracer antibodies reversed (anti-common ␤1 capture antibody, with anti-common ␤2 and anti-hCG dimer tracer antibodies). This assay also detects nicked and non-nicked hCG and free ␤-subunit. It does not detect urine ␤-core fragment. The Bayer Corporation Immuno-1 TM hCG assay uses a similar mixture of antibodies. It uses a combination of an anti-common ␤2 and anti-hCG dimer antibody to capture hCG and related molecules and an anti-common ␤1 antibody to label captured molecules. This assay also detects nicked and non-nicked hCG and free ␤-subunit. The table in the review article also listed a Bayer Immuno-1 ␤-core fragment assay (1). This assay is strictly a research assay and is not for sale.
As described in this and other review articles by Dr. Cole (1-3) , detection of nicked hCG, hCG missing the ␤-subunit C-terminal, and free ␤-subunit may be important for monitoring hCG immunoreactivity in patients with trophoblast disease, in patients with cancer, for pregnant women with aneuploid fetuses, and for following the clearance of hCG after parturition or termination of pregnancy. The Chiron Diagnostics Magic Lite and the Chiron Diagnostics ACS:180 total hCG assays and the Bayer Immuno-1 hCG assay detect these important hCG-related molecules and may be useful for these pregnancy-and cancer-related applications. 
Tissue Polypeptide Antigen as a Putative Indicator of Apoptosis
To the Editor: Tissue polypeptide antigen (TPA) is a keratin-derived product containing fragments of cytokeratins (CKs) 8, 18, and 19 (1) . The determination of serum TPA has been used in the management of cancer patients (2, 3) . TPA has also been measured in tissue extracts (4, 5). In our experience, high TPA contents in the cytosols of breast cancer specimens were associated with longer relapse-free periods and overall survival rates (4). This was an unexpected relationship and seemed not to be supported by a clear biological rationale.
It has been assumed that during mitosis the mother cell expels its cytokeratin in a degraded form to the cellular environment. This behavior may explain both the high serum cytokeratins in more aggressive tumors and the lower cytosolic TPA found in tumors with a worse prognosis. Because the reconstruction of cytoskeleton takes place soon after cell division, the latter hypothesis regarding tissue cytokeratin distribution was considered poorly tenable (6). Moreover, the release of TPA from MCF7 cells seems to be unrelated to proliferation (7), at least in the experimental conditions used by the authors.
Cytokeratin filaments are insoluble or poorly soluble in aqueous systems unless they are first processed to soluble fragments (8). We hypothesized that the fragmentation of the cytokeratin filaments could occur during cell necrosis, often occurring in rapidly growing tumors, or otherwise during cell apoptosis, a protective phenomenon against uncontrolled cellular growth.
If this were true, the soluble fragments of CKs produced in rapidly growing and necrotic tumors should be very quickly eliminated in the bloodstream. On the other hand, in tumors with active apoptosis, the CK fragments should be produced, kept in the apoptotic cells, and therefore be detectable in the cytosolic fraction and undetectable in the serum. This hypothesis could explain why high cytosolic concentrations of TPA indicate a good prognosis. In addition, it could also support the finding of high TPA in serum of patients with more rapidly growing tumors. Therefore, we were prompted to evaluate the relationship between TPA concentrations and the apoptotic phenomenon in cell lines.
TPA concentrations were evaluated MCF7 cells (5 ϫ 10 6 /flask) were grown as monolayer cultures in Dulbecco's modified Eagle's medium supplemented with fetal calf serum (20 mL/L) in T75 cm 2 plastic flasks. The cells were allowed to attach for 24 h. The seeding medium was removed and replaced by experimental medium alone [control conditions (F)], medium containing 2 mmol/L of sodium butyrate (Ⅺ), or 2.5 mg/L of camptothecin (E). After 24, 48, and 72 h, culture medium was removed and centrifuged to collect floating cells; adherent cells were removed from the flask with a trypsin (0.5 g/L) and EDTA (0.2 g/L) solution. Solid lines represent the cell extract; dashed lines represent the cell culture medium. Arrows represent the steps in which apoptosis was detected.
